Lys157

Site Information
kLKEkyEkDIAAyRA SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 466080

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 )
Relevant cell line - cell type - tissue:	A549 (pulmonary) ( 4 ) , HCT116 (intestinal) ( 10 , 11 , 12 ) , HCT8/S11 (intestinal) ( 13 ) , HeLa (cervical) ( 1 ) , Jurkat (T lymphocyte) ( 2 , 4 ) , MV4-11 (macrophage) ( 4 ) , OCI-ly3 (B lymphocyte) ( 6 , 7 , 8 ) , Reh (B lymphocyte) ( 5 ) , SW620 (intestinal) ( 9 )

Upstream Regulation
Treatments:	vorinostat ( 4 )

References
1	Weinert BT, et al. (2013) Lysine succinylation is a frequently occurring modification in prokaryotes and eukaryotes and extensively overlaps with acetylation. Cell Rep 4, 842-51 23954790 Curated Info
2	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
3	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
4	Choudhary C, et al. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-40 19608861 Curated Info
5	Cherry J (2007) CST Curation Set: 2708; Year: 2007; Biosample/Treatment: cell line, Reh/SAHA 3h; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
6	Cherry J (2007) CST Curation Set: 2510; Year: 2007; Biosample/Treatment: cell line, OCI-ly3/DMSO; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
7	Cherry J (2007) CST Curation Set: 2437; Year: 2007; Biosample/Treatment: cell line, OCI-ly3/DMSO; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
8	Cherry J (2007) CST Curation Set: 2441; Year: 2007; Biosample/Treatment: cell line, OCI-ly3/SAHA 6h; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
9	Li Y (2006) CST Curation Set: 2115; Year: 2006; Biosample/Treatment: cell line, SW620/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
10	Li Y (2006) CST Curation Set: 1998; Year: 2006; Biosample/Treatment: cell line, HCT116/serum starved; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
11	Li Y (2006) CST Curation Set: 1999; Year: 2006; Biosample/Treatment: cell line, HCT116/serum starved &'\|\|' EGF; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
12	Li Y (2006) CST Curation Set: 2000; Year: 2006; Biosample/Treatment: cell line, HCT116/serum starved &'\|\|' EGF; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
13	Li Y (2006) CST Curation Set: 1476; Year: 2006; Biosample/Treatment: cell line, HCT8/S11/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441 Curated Info